Alderman S, Kailas S, Goldfarb S, et al. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy.
J Clin Gastroenterol.
1994;19:242 - 247.
[No authors listed]. From the Centers for Disease Control and Prevention. Chaparral-induced toxic hepatitis - California and Texas, 1992.
JAMA.
1992;268:3295, 3298.
Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications.
JAMA.
1995;273:489 - 490.
Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf.
J Clin Gastroenterol.
1990;12:203 - 206.
Smith BC, Desmond PV. Acute hepatitis induced by ingestion of the herbal medication chaparral [letter].
Aust N Z J Med.
1993;23:526.
Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity.
Arch Intern Med.
1997;157:913 - 919.
Jim LK, Gee JP. Adverse effects of drugs on the liver. In: Young LY, Koda-Kimble MA (eds).
Applied Therapeutics: The Clinical Use of Drugs.
Vancouver, Wash: Applied Therapeutics, Inc.; 1995:26.1 - 26.17.
A to Z Drug Facts
[book on CD-ROM]. 2nd ed. St. Louis, Mo: Facts and Comparisons; 2000.
Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects.
Clin Pharmacol Ther.
2000;67:201 - 214.
A to Z Drug Facts
[book on CD-ROM]. 2nd ed. St. Louis, Mo: Facts and Comparisons; 2000.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D - 29D.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated [abstract].
J Am Coll Cardiol.
2000;35(2 suppl A):A326.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q
10
during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med.
1997;18(suppl):S137 - S144.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ
10
-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;33:226 - 229.
Mortensen SA, Vadhanavikit S, Muratsu K, et al. Coenzyme Q
10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure.
Int J Tissue React.
1990;12:155 - 162.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q
10
during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med.
1997;18(suppl):S137 - S144.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ
10
-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;33:226 - 229.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans.
Proc Natl Acad Sci USA.
1990;87:8931 - 8934.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans.
Proc Natl Acad Sci USA.
1990;87:8931 - 8934.
Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ
10
preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Int J Clin Lab Res.
1994;24:171 - 176.
Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Heart.
2001;85:544 - 548.
Sugimoto Ki K, Ohmori M, Tsuruoka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin.
Clin Pharmacol Ther. 2001;70:518 - 524.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D - 29D.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated.
J Am Coll Cardiol.
2000;35(suppl A):326.
Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
Am J Cardiol.
2001;87:476 - 479.
Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy.
Am Heart J.
2002;143:514 - 518.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.